WO2007114948A3 - Methods and compositions for inhibiting cell death - Google Patents

Methods and compositions for inhibiting cell death Download PDF

Info

Publication number
WO2007114948A3
WO2007114948A3 PCT/US2007/008507 US2007008507W WO2007114948A3 WO 2007114948 A3 WO2007114948 A3 WO 2007114948A3 US 2007008507 W US2007008507 W US 2007008507W WO 2007114948 A3 WO2007114948 A3 WO 2007114948A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cell death
disease
release
cardiac
Prior art date
Application number
PCT/US2007/008507
Other languages
French (fr)
Other versions
WO2007114948A2 (en
Inventor
Robert M Friedlander
Original Assignee
Brigham & Womens Hospital
Robert M Friedlander
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital, Robert M Friedlander filed Critical Brigham & Womens Hospital
Publication of WO2007114948A2 publication Critical patent/WO2007114948A2/en
Publication of WO2007114948A3 publication Critical patent/WO2007114948A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin

Abstract

The invention relates to products and methods for inhibiting cytochrome c release and/or cell death. The methods of the invention are useful to prevent and treat cytochrome c release-associated diseases and/or disorders such as Alzheimer's disease, Parkinson's disease; Huntington's disease; ALS, epilepsy; stroke, head trauma; spinal cord injury; perinatal hypoxic injury; retinal degeneration; cerebral or other end-organ ischemia inducing cell death associated with a neurosurgical, vascular, cardiac, or transplantation surgery; myocardial infarction; perioperative neuroprotection during carotid endarterectomy; carotid and cardiac stents; abdominal aortic aneurism (AAA) repair; or diabetes.
PCT/US2007/008507 2006-04-04 2007-04-04 Methods and compositions for inhibiting cell death WO2007114948A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78901706P 2006-04-04 2006-04-04
US60/789,017 2006-04-04

Publications (2)

Publication Number Publication Date
WO2007114948A2 WO2007114948A2 (en) 2007-10-11
WO2007114948A3 true WO2007114948A3 (en) 2008-05-08

Family

ID=38564148

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/008507 WO2007114948A2 (en) 2006-04-04 2007-04-04 Methods and compositions for inhibiting cell death

Country Status (1)

Country Link
WO (1) WO2007114948A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ579229A (en) 2007-01-25 2011-07-29 Verva Pharmaceuticals Ltd Insulin sensitisers and methods of treatment
MX2014014316A (en) * 2012-05-24 2015-07-06 Verva Pharmaceuticals Ltd A method of weight reduction.
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
WO2017059070A1 (en) 2015-09-29 2017-04-06 Amag Pharmaceuticals, Inc. Crystalline and amorphous form of 17-a- hydroxyprogesterone caproate
US10780094B2 (en) 2016-07-22 2020-09-22 New York University Use of carbonic anhydrase inhibitors for treatment of neurological and psychiatric disorders

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4299838A (en) * 1974-12-23 1981-11-10 La Cooperation Pharmaceutique Francaise Tryptophan derivatives having an increased effect on the central nervous system
US5681711A (en) * 1995-03-27 1997-10-28 University Of California-Los Angeles Method for promoting apoptosis in mammalian neual cells
US5876750A (en) * 1994-04-28 1999-03-02 Alza Corporation Effective therapy for epilepsies
US6024977A (en) * 1990-11-01 2000-02-15 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US20040072205A1 (en) * 2002-05-01 2004-04-15 Friedlander Robert M. Methods for treating neuronal disorders
US20060122160A1 (en) * 2004-06-30 2006-06-08 Dinesh Patel Co-administration of dehydroepiandrosterone (DHEA) congener with parthenolide for treating inflammation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3795739A (en) * 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4299838A (en) * 1974-12-23 1981-11-10 La Cooperation Pharmaceutique Francaise Tryptophan derivatives having an increased effect on the central nervous system
US6024977A (en) * 1990-11-01 2000-02-15 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5876750A (en) * 1994-04-28 1999-03-02 Alza Corporation Effective therapy for epilepsies
US5681711A (en) * 1995-03-27 1997-10-28 University Of California-Los Angeles Method for promoting apoptosis in mammalian neual cells
US20040072205A1 (en) * 2002-05-01 2004-04-15 Friedlander Robert M. Methods for treating neuronal disorders
US20060122160A1 (en) * 2004-06-30 2006-06-08 Dinesh Patel Co-administration of dehydroepiandrosterone (DHEA) congener with parthenolide for treating inflammation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COIMBRA ET AL., STROKE, vol. 27, 1996, pages 1558 - 1585 *
MACINTYRE ET AL., CANADIAN M.J., vol. 85, 8 July 1961 (1961-07-08), pages 67 - 69 *
WANG ET AL., PNAS, vol. 100, no. 18, 2 September 2003 (2003-09-02), pages 10483 - 1487 *
ZHU ET AL., NATURE, vol. 417, 2002, pages 74 - 78 *

Also Published As

Publication number Publication date
WO2007114948A2 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
WO2007114948A3 (en) Methods and compositions for inhibiting cell death
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
WO2008155534A3 (en) Neurosteroid compounds
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
WO2010088408A3 (en) Subunit selective nmda receptor antagonists for the treatment of neurological conditions
WO2018015573A3 (en) Trem2 cleavage modulators and uses thereof
WO2009003669A3 (en) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
WO2010028088A3 (en) Sulfur-linked compounds for treating opthalmic diseases and disorders
WO2007087441A3 (en) Substituted aromatic compounds for inflammation and immune-related uses
WO2009151598A8 (en) Diazacarbazoles and methods of use
WO2008063775A3 (en) Medical devices including hardened alloys
WO2005112619A3 (en) Novel gene disruptions, compositions and methods relating thereto
MY167602A (en) Amine derivatives compounds for treating ophthalmic diseases and disorders
GB0503506D0 (en) Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
ECSP11011051A (en) NEW COMPOUNDS 578
WO2010037135A3 (en) Compounds for reversing and inhibiting protein aggregation, and methods for making and using them
WO2009143178A3 (en) Pde10 inhibitors and related compositions and methods
WO2007076228A3 (en) 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders
NO20085323L (en) Melted, tricyclic sulfonamide inhibitors of gamma secretase
WO2006127702A3 (en) Analogs of glycyl-prolyl-glutamate
WO2007035722A8 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
WO2008157425A3 (en) Compounds for inhibiting protein aggregation, and methods for making and using them
TW200602297A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
WO2007009087A3 (en) Methods and products for treatment of diseases
WO2011091435A3 (en) Methods of treating liver disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07754942

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07754942

Country of ref document: EP

Kind code of ref document: A2